- What Is Tesamorelin?
- What Tesamorelin Is FDA-Approved For
- What Tesamorelin Is Not Approved For
- What the Research Shows
- Safety, Warnings, and Contraindications
- Egrifta WR vs Egrifta SV
- How Tesamorelin Is Discussed at Vitalé
- Peptide Consultations in Manasquan and Online
- Schedule an Online Consultation
Prescription-Based, Medically Supervised Consultations in Manasquan and Online
Vitalé provides peptide consultation services from its Manasquan, NJ clinic and may offer online consultations for eligible patients where permitted. Availability depends on your location, medical history, treatment goals, provider review, and applicable state requirements.
Tesamorelin is often marketed online as a “fat-loss” or “longevity” peptide. That framing is misleading.
Tesamorelin is a prescription medication with a specific FDA-approved indication. It is not approved for general weight loss, anti-aging, or body recomposition in the general population.
At Vitalé, Tesamorelin is discussed clinically and carefully through secure online medical consultations, available to patients across the United States. The focus is on what Tesamorelin is approved for, who it is not appropriate for, what the risks are, and whether it fits your medical profile at all
What Is Tesamorelin?
Tesamorelin is a growth hormone–releasing hormone (GHRH) analogue. It works by stimulating the pituitary gland to increase endogenous growth hormone secretion, which in turn raises insulin-like growth factor-1 (IGF-1) levels.
Key point upfront:
Tesamorelin is not a wellness supplement. It is a prescription drug with defined FDA labeling, contraindications, and monitoring requirements.
What Tesamorelin Is FDA-Approved For
Tesamorelin, marketed as Egrifta SV and the newer formulation Egrifta WR, is FDA-approved for:
- Reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy
This indication is specific and narrow. The clinical trials supporting approval were conducted in people living with HIV who developed visceral adipose tissue accumulation related to antiretroviral therapy.
FDA labeling and payer policy summaries also state clearly:
- Tesamorelin is not indicated for weight-loss management
- Overall body weight is generally described as weight-neutral
What Tesamorelin Is Not Approved For
If you see Tesamorelin promoted for the following, that should raise questions:
- General weight loss
- “Belly fat reduction” in non-HIV patients
- Anti-aging or longevity therapy
- Body recomposition for the general population
These uses are not aligned with FDA-approved labeling and often overstate what the evidence supports. A responsible clinic does not blur this line.
What the Research Shows
Clinical trials in people living with HIV demonstrate that Tesamorelin can:
- Reduce visceral adipose tissue in the approved population
- Increase growth hormone and IGF-1 levels